Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

AIM ImmunoTech

Tracked across 3 events · 22 articles · First seen Feb 11, 2026 · Last active Jun 16, 2026

Sentiment
42
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 -20
Business
Impact: AIM ImmunoTech conducted a rights offering to raise capital, which resulted in approximately $1.8 million in subscriptions, significantly less than the initially expected $12 million, indicating a shortfall in fundraising.
Feb 11, 2026 · 6 articles
4 70
Tech
Impact: AIM ImmunoTech Inc. is the developer of Ampligen and is reporting positive interim results from its Phase 2 DURIPANC study, which could lead to significant value inflection for the company.
Jun 01, 2026 · 10 articles
4 75
Regulatory
Impact: AIM ImmunoTech Inc. regained compliance with NYSE American's listing standards, resolving its stockholders' equity deficiency through several financing transactions. This positive development removes the 'below compliance' indicator from its trading symbol and improves its market standing.
Jun 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Track AIM ImmunoTech live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.